Company intelligence / Profile preview

Nuprim

Bethesda, Maryland, USA

Ownership: Private
Development stage: Other

Overview

Nuprim was a clinical-stage biopharmaceutical company focused on the development of iclaprim, a novel diaminopyrimidine antibiotic. Founded in 2014 by former executives of Arpida AG, Nuprim acquired the rights to iclaprim from Acino Pharma and Life Sciences Management Group. In April 2015, the company merged with Motif Bio. Under Motif Bio's stewardship, iclaprim completed Phase 3 trials for acute bacterial skin and skin structure infections (ABSSSI), demonstrating non-inferiority to vancomycin. However, it failed to obtain FDA approval in 2019 due to safety concerns regarding liver toxicity.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Acino PharmaLife Sciences Management Group

Beyond the preview

Go deeper on Nuprim.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuprim.

Explore the full profile